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Abstract
Microarray experiments have identified novel candidate genes in animal models of asthma. In the
near future, genomics may have a profound impact on the way we think about this common and
complex disease.
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People with asthma have recurrent episodes of airway narrowing
that can cause wheezing, coughing, and shortness of breath.
Episodes of airway narrowing are often triggered by respiratory
infections or allergens. Nearly all asthmatics have exaggerated
airway narrowing in response to a variety of bronchoconstrictor
agents, a phenomenon that can be documented by measuring
changes in lung function following inhalation of the pharma-
cologic agent methacholine in the pulmonary-function
laboratory. Several pathological abnormalities, including
airway inflammation and airway remodeling (thickening of the
smooth muscle layer, increased epithelial cell mucus content,
and subepithelial fibrosis), are commonly seen in asthma [1].
Although some of the underlying mechanisms have been eluci-
dated in recent years, much more needs to be done to gain a
clearer understanding of the many genetic and environmental
factors that contribute to the development of various forms of
asthma. Asthma prevalence and morbidity has increased
dramatically in recent decades, and there is an urgent need for
better approaches to prevention and treatment. Some investi-
gators have begun to use DNA microarrays to advance our
understanding of asthma [2-4]; their results demonstrate that
microarrays can accelerate the discovery process and suggest
that functional genomics may soon help lead to a more
complete understanding of the molecular nature of asthma. 
Identifying differentially expressed genes in
animal models
Microarrays are often used as a high-throughput tool for the
identification of differentially expressed genes, and they have
been used to study animal models of allergen-induced asthma.
Zou et al. [2] used arrays containing 40,000 human cDNA
probes to analyze lung gene expression in a monkey model.
They identified 149 genes whose expression was changed by at
least 2.5-fold at 4, 18, or 24 h after inhalation of Ascaris suum
antigen, or 24 h after treatment with interleukin 4 (IL-4), a
cytokine implicated in asthma pathogenesis. These differen-
tially expressed genes included several novel genes, together
with many for which a role in asthma pathogenesis had been
implicated in previous studies, such as chemokines and other
inflammation-associated genes, and matrix proteins and pro-
teases likely to be involved in airway remodeling. RT-PCR
analysis of a subset of the genes identified in the microarray
experiments verified that most were differentially expressed,
often to a greater extent than was estimated from the micro-
arrays [2]. Technical issues, including limited sample size and
a dependence on interspecies hybridization, probably account
for the relatively small number of differentially expressed
genes detected in the microarray experiments; nonetheless,
this study demonstrates that microarrays are useful for
describing patterns of gene expression in asthma models and
for identifying novel candidate genes for further study.
More recently, Zimmermann and colleagues [3] examined
gene expression in two widely used murine models of allergic
asthma. Mice were challenged with intranasal ovalbumin or
Aspergillus extract or a control and lungs were harvested 18
h later. Lung gene expression was analyzed for two or three
mice per treatment using oligonucleotide microarrays with
12,422 probe sets (Affymetrix U74Av2 GeneChips). Eachallergen caused a two-fold or greater increase in the expression
of genes recognized by roughly 500 probe sets (p < 0.05);
this represents somewhat fewer than 500 distinct genes
because of the redundancy of the probe sets. Nearly 300
genes were increased by both allergens and were therefore
considered to represent ‘asthma signature’ genes [3].
Of the hundreds of differentially expressed genes, the
investigators focused their attention on three functionally
related genes that were not previously known to be involved
in asthma pathogenesis but were induced in both asthma
models [3]. These genes, the cationic anion transporter
CAT2 (SLC7A2), arginase I and arginase II, play a role in the
metabolism of L-arginine: CAT2 transports L-arginine, and
arginase I and arginase II convert L-arginine to L-ornithine.
Increases in expression of these genes might be expected to
result in increased production of L-ornithine. This could be
relevant to airway remodeling, as L-ornithine is a precursor
of polyamines such as putrescine, spermidine and spermine,
which help control cell proliferation, and of proline, a major
constituent of collagens. 
The investigators took several approaches to validating the
microarray data. First, they used northern blot analysis to
confirm that the arginases (especially arginase I) were
strongly upregulated in both allergic models and in other
models of asthma induced by administration of the
cytokines IL-4 and IL-13. Second, they performed in situ
hybridization and found intense arginase I staining in
macrophages from the lungs of allergen-challenged mice.
Third, they showed that both arginase enzymatic activity and
levels of putrescine were increased in the lungs of allergen-
challenged mice. Finally, they showed higher expression of
arginase I in lung macrophages and airway epithelial cells
from humans with asthma than in control subjects. Although
further work will be required to establish whether arginase
plays a causal role in asthma pathogenesis, this study provides
a fine illustration of how microarray data can be used to
inspire novel areas of investigation. 
Other publicly accessible microarray datasets [5] provide
more information about the pattern of arginase I expression
in different lung-disease models. Arginase I expression was
increased in a model of allergic asthma triggered by a different
allergen, ragweed pollen, lending further support to the idea
that arginase I induction is a general feature of allergic airway
disease. Another publicly available dataset [5] documents
gene-expression changes in lungs following treatment with
bleomycin, an agent that induces lung fibrosis in some sus-
ceptible strains of mice. Arginase I expression was increased
following bleomycin treatment of fibrosis-susceptible
C57BL/6 mice. Although the overall pattern of gene expression
was similar in susceptible C57BL/6 and resistant BALB/c
mice, bleomycin had little or no effect on arginase I expression
in BALB/c mice [5]. This observation is consistent with the
possibility that arginase I is involved in both allergen- and
bleomycin-induced fibrosis, and suggests that strain-specific
differences in arginase I expression might help to determine
susceptibility to bleomycin-induced fibrosis.
Microarrays can identify large numbers of genes that are
differentially expressed in asthma models and there is a
clear need for creative strategies to allow investigators to
identify which of these genes play key roles in asthma
pathophysiology. One study, by Karp and colleagues [4],
provides an outstanding example of the combined use of
microarray and genetic mapping data for asthma-gene
discovery. These investigators had previously shown that
strain-related differences in allergen-induced airway hyper-
reactivity to acetylcholine could be mapped to two loci on
chromosome 2 [6]. Oligonucleotide arrays were used to
measure lung gene expression in susceptible (A/J) and
resistant (C3H/HeJ) inbred strains and in genetically
heterogeneous mice produced by interbreeding of these two
strains. A total of 739 genes were differentially expressed
between the inbred susceptible and resistant strains, but
only 21 genes had expression patterns that correlated with
susceptibility in the genetically heterogeneous mice. One of
these genes, C5, mapped to one of the previously defined
loci on chromosome 2 [4,6]. C5 encodes complement factor
5, and the A/J mouse strain carries a null mutation in the
C5  gene. Additional experiments found correlations
between the C5 genotype and airway responsiveness in
larger groups of mice and also demonstrated the effects of
C5 on the production of IL-12, a cytokine that is known to
have a role in asthma pathogenesis [7]. This work illustrates
the power of combining genomic and genetic data in the
search for asthma candidate genes. 
Towards the clinic
As microarray technology is more widely applied to asthma
models, we can look forward to the identification of more
genes involved in pathogenesis. Microarray analyses of the
effects of targeted interventions, such as transgenic
overexpression of cytokines or gene targeting, could help
to elucidate the contributions of specific molecules and
pathways. Although whole-lung expression profiling has
been shown to be valuable for the investigation of asthma
and other lung disease models [2-4,8], there are undoubtedly
important cell-type-specific effects that are difficult to
detect in complex mixtures of cells. Microarray analysis
has shown that airway epithelial and smooth muscle cells
and lung fibroblasts all responded to the asthma mediator
IL-13 with extensive changes in gene expression, but the
specific genes affected in each cell type were almost com-
pletely different [9]. Approaches such as laser-capture
microdissection and flow-cytometric sorting, in combination
with emerging nucleic acid amplification methods and
more sensitive detection methods, should be useful for
dissecting the contributions of specific cell types to asthma
pathogenesis in vivo.
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Genome Biology 2003, 4:232We can also expect to see microarrays being deployed for
studies of people with asthma. Recent microarray studies of
human cancers show the potential utility of microarrays for
disease classification and prognosis and suggest that
microarray data may be useful in selecting appropriate ther-
apies [10-12]. Asthma microarray studies will be challenging
because of the requirement for recruiting large, clinically
well-characterized cohorts of subjects and the difficulties
inherent in obtaining suitable tissue for study. As these
obstacles are overcome, microarray-based approaches may
help identify distinct classes of asthma, something that has
proved difficult using conventional clinical criteria. Comparing
gene expression patterns in classes of asthmatic individuals
with those in various animal models may shed new light on
asthma mechanisms and suggest focused therapeutic
approaches for different forms of asthma. 
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